Aplex Bio

Executive Summary

Aplex Bio is a Swedish biotechnology company founded in 2020 that is developing Hyperplex PCR (hpPCR), a next-generation PCR technology enabling ultra-sensitive, highly specific detection of up to 100 targets in a single well with single-nucleotide resolution. The platform aims to bridge the gap between traditional PCR and next-generation sequencing (NGS), providing a powerful yet accessible molecular analysis tool for research and diagnostic applications. By significantly increasing multiplexing capability without sacrificing sensitivity or specificity, hpPCR has the potential to transform areas such as liquid biopsy, infectious disease testing, and genetic screening. The company is currently in the early development stage and has not disclosed funding or valuation, but its innovative approach positions it well within the growing genomics and molecular diagnostics market.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement50% success
• Q4 2026First Commercial Product Launch (hpPCR Kit for Research Use)40% success
• Q1 2027Key Partnership with a Diagnostics Company35% success